Gabe Holdsman is currently senior vice president, legal & general counsel of Americas for PTC Therapeutics, a science-led, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders.

Mr. Holdsman started his legal career at Conrad O’Brien, where he trained and litigated various matters including commercial disputes, medical malpractice defense, product liability defense and class actions.

His first in-house assignment was with AmerisourceBergen, a global pharmaceutical wholesaler and distributor. His initial focus was managing the company’s litigation, investigations and compliance matters, but his interest turned towards the commercial business (i.e. supply/distribution agreements, government contracts, acquisitions, etc.).

In 2005, he joined Auxilium Pharmaceuticals, a publicly traded specialty pharmaceutical company, where he enjoyed a broader remit including corporate governance, SEC filings, health care compliance and legal support for all aspects of a growing pharma business.

In 2010, he moved to BTG, a London-based company with an office in Conshohocken, Pennsylvania and a plan to re-make itself as a global rare-disease pharmaceutical business. Mr. Holdsman helped set up the initial U.S. structure, played a key role in hiring and training the initial teams and supported the subsequent global expansion. He led the growth and management of the global legal team, oversaw legal support for the growing business and supported multiple acquisitions and deals. He also led the company through several material litigation matters and the successful resolution of a DOJ investigation.

In April 2018, Mr. Holdsman joined PTC Therapeutics, a global biopharmaceutical company based in South Plainfield, New Jersey that focused on treating rare disorders. Mr. Holdsman is responsible for managing the global legal team, as well as legal support for North America and Latin America businesses. Shortly after joining PTC, he led legal support for the acquisition of Agilis Biotherapeutics, helping to bring PTC into the exciting and innovative world of gene technology.